Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

A legfontosabb adatok

Ki végzi
Eli Lilly and Company
Hol
Toronto (Kanada)A helyszín megnézéseMég 3 másik országban, 8 helyszínen
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
48 fő, tervezett
Kezdés
2023. szept. 15.
Várható befejezés
2029. dec.
A vizsgálat típusa
Beavatkozással járó, 6 csoport
A vizsgált kezelések
  • AAVAnc80-hOTOF via Akouos Delivery Device
  • AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
A regiszteradat frissítve
2026. szeptember 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people of any age with hearing loss in both ears caused by changes in the otoferlin gene. They get a one-time gene therapy, AAVAnc80-hOTOF, placed in one or both ears.

Életkor
Any age, depending on the study group. Some early groups needed people aged 7 to 17 years or at least two years old.
Nem
All sexes can join.
A betegség stádiuma
Profound (Part A) or severe to profound (Parts B, C and D) sensorineural hearing loss in both ears, measured by ABR (a brain response hearing test).
Korábbi kezelés
No cochlear implant in the ear that gets the gene therapy. No investigational drug in a trial in the 6 months before treatment. No earlier gene therapy trial, except AK-OTOF-101 for Part D. Part D is for people already treated in one ear in this trial.
Biomarker vagy leletérték
At least two mutations in the otoferlin gene. Preserved distortion product otoacoustic emissions (DPOAEs), a test showing the inner ear's hair cells still respond to sound.

A részvétel fő kizáró okai

  • Ear infections that keep coming back
  • Abnormal ear structure or other ear problems
  • Health problems that rule out surgery, anesthesia or gene therapy
  • Cochlear implant in the ear to be treated
  • Investigational drug in the past 6 months or any earlier gene therapy trial (except AK-OTOF-101 for Part D)

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Egyéb feltételek

  • Criteria for Inclusion:
  • Participants may be of any age, based on Cohort Criteria
  • At least two mutations in the otoferlin gene
  • Clinical presentation of Profound (Part A) or Severe to Profound (Parts B, C, and D) bilateral sensorineural hearing loss as assessed by ABR
  • Preserved distortion product otoacoustic emissions (DPOAEs)
  • Able and willing to comply with all study requirements, including willingness to participate in a separate long term follow-up study after completion of this trial; Criteria for Exclusion:
  • Persistent ear infections, anatomic or other abnormalities of the ear, and/or medical conditions that would contraindicate undergoing surgery, anesthesia, and/or administration of investigational gene therapy
  • Cochlear Implant(s) in the ear(s) to receive AAVAnc80-hOTOF
  • Prior participation in a clinical trial with an investigational drug, within six months prior to administration, or any prior participation in a gene therapy clinical trial (with the exception of AK-OTOF-101 for Part D participants)

Helyszínek itt: Kanada

Még 3 másik országban, 8 helyszínen

  • Toronto, OntarioHospital not named in the registryContact: Lilly Clinical TrialsNo longer taking part

A vizsgálatról

Mit akar kideríteni a vizsgálat

Part A of this trial evaluated the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF (LY888891) and evaluated the Akouos Delivery Device, together with the Precision Delivery Mechanism (as applicable), to safely achieve the intended product performance.

A teljes eredeti leírásKevesebb

Part B of the trial is an open-label, global expansion phase to confirm the efficacy and safety of one dose level of AAVAnc80-hOTOF administered in one or both ear(s). Part B will also evaluate the Intracochlear Delivery System (IDS), which consists of the Akouos Delivery Device, the Precision Delivery Mechanism, and an off-the-shelf syringe.

Part C is a region-specific expansion phase. Part C participants will receive the same dose level of AAVAnc80-hOTOF as participants in Part B, in one or both ear(s) utilizing the IDS.

Part D is a sequential administration phase that allows participants who received AAVAnc80-hOTOF previously in a single ear to receive AAVAnc80-hOTOF administration in the other ear utilizing the IDS.

A vizsgálat 6 csoportja

  • Part A: Cohort 1a and Cohort 1bA vizsgált kezelés

    Cohort 1a: Two participants aged 7 to 17 years old (inclusive) to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device Cohort 1b: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age

    Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device

  • Part A: Cohort 2A vizsgált kezelés

    Cohort 2: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 2) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age

    Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device

  • Part A: Bilateral ExpansionA vizsgált kezelés

    Bilateral Expansion: up to eight eligible participants of any age, and no cochlear implants, may be eligible for enrollment into the Bilateral Expansion Cohort (simultaneous bilateral administration of AAVAnc80-hOTOF).

    Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

  • Part BA vizsgált kezelés

    Part B: Sixteen participants of any age will be enrolled to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.

    Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

  • Part CA vizsgált kezelés

    Up to ten eligible participants of any age will be enrolled in a region-specific expansion phase to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.

    Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

  • Part DA vizsgált kezelés

    Participants of any age may be enrolled into Part D, which is a sequential administration phase that allows participants who received unilateral administration of AAVAnc80-hOTOF in AK-OTOF-101 (Parts A, B, or C) the option to receive dose administration of AAVAnc80-hOTOF in the contralateral ear after completing the Year 1 visit.

    Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. szeptember 29.